Gaorong Capital Leads New Round In Chinese AI-Based Microbiome Drug Developer

Login to View

Chinese artificial intelligence (AI)-based microbiome drug developer Xbiome has completed a new funding round led by the country’s venture capital firm Gaorong Capital and a Shenzhen-based investment company, according to a statement released on Monday.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in